• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

UK covid19 drug trial of over 100 existing drugs [Feb 4th 2022]

godlovesatrier

Senior Member
Messages
2,561
Location
United Kingdom
https://www.ox.ac.uk/news/2022-02-0...cus-repurposing-existing-anti-viral-therapies

The project, led by Queen’s University Belfast and funded by the Medical Research Council, will bring together experts from Queen’s, the University of Liverpool and the University of Oxford. The team will use a data-driven approach to identify novel drug combinations that are effective in tackling SARS-CoV-2, the causative agent of COVID-19.

Despite the development of vaccines and drugs at an unprecedented pace to prevent and treat infection, there remains a huge gap in the development of antiviral therapies. Antiviral drugs are used specifically to treat viral infections by killing or preventing the growth of viruses.

The research project will initially screen 138 drugs with known antiviral activity against SARS-CoV-2 to assess and identify combinations that enhance their antiviral potential. The most effective combinations will be presented to national organisations including the UK Antiviral Task Force and UK-CTAP, evidencing the need to bring the treatments forward to clinical trials phase.

Professor Miles Carroll, Principal Investigator from Oxford University, said: ‘We are excited to join this anti-viral consortium with the ultimate aim of providing new drug candidates for the Antiviral Task Force. The fact that we are focussing on those drugs that are already licensed for human use, means those with significant anti-SARS-CoV-2 activity can be rapidly assessed in humans where they could have a significant impact on the disease burden in the community.’
 
Last edited by a moderator: